AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31201877 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS (question: 'How bad has your breathlessness felt at its worst over the past 24 hours?')
Number of subjects: 22
Study 27900818 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN biopsy without ALND
Number of subjects: 800
Study 27900818 — intervention group
Group type: COMPARATOR
Intervention: SLN biopsy with completion ALND
Number of subjects: 800
Study 27900818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative FS
Number of subjects: 800
Study 27900818 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting FS
Number of subjects: 800
Study 27900818 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of Z0011
Number of subjects: 800
Study 27900818 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting ALND
Number of subjects: 800
Study 27900818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative FS analysis
Number of subjects: 800
Study 26078574 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 8 weeks
Number of subjects: 305
Study 26078574 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg once daily for 2 weeks
Number of subjects: 305
Study 23522788 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HAART patients
Number of subjects: 250
Study 21528594 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on single-point (Shiqizhui EX-B 8)
Number of subjects: 63
Study 21528594 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on multi-point (Shiqizhui EX-B 8, Diji SP 8, Ciliao BL 32, Sanyinjiao SP 6)
Number of subjects: 63
Study 19401665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil (group SR)
Number of subjects: 50
Study 19401665 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone (group S)
Number of subjects: 50
Study 16723327 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling-of-Knowing task in patients with schizophrenia
Number of subjects: 32
Study 16723327 — intervention group
Group type: COMPARATOR
Intervention: Feeling-of-Knowing task in control subjects
Number of subjects: 32
Study 15109760 — intervention group
Group type: COMPARATOR
Intervention: Pes planus group
Number of subjects: 0
Study 11157326 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg vitamin D3/d
Number of subjects: 61
Study 11157326 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg vitamin D3/d
Number of subjects: 61
Study 11157326 — intervention group
Group type: COMPARATOR
Intervention: Control group (not taking vitamin D3)
Number of subjects: 61
Study 9622114 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Limit of Vulnerability (ULV) measurement
Number of subjects: 13
Study 9622114 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 13
Study 9622114 — intervention group
Group type: COMPARATOR
Intervention: CPK-MB assessment
Number of subjects: 13
Study 7938648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dexaven)
Number of subjects: 0
Study 7938648 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone (Control)
Number of subjects: 0
Study 3077320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (stress inoculation training)
Number of subjects: 69
Study 31982882 — intervention group
Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (OL-HDF)
Number of subjects: 15
Study 31982882 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis (HF-HD)
Number of subjects: 15
Study 31982882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis excluding outliers
Number of subjects: 15
Study 30502505 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag (3 mg once daily for up to 7 days)
Number of subjects: 96
Study 30502505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 27858108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib with food
Number of subjects: 0
Study 27858108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib with ranitidine (antacid)
Number of subjects: 0
Study 27858108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (general)
Number of subjects: 0
Study 26453483 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-tip diet (6-TD)
Number of subjects: 57
Study 26453483 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LPD) 0.8 g/kg/day
Number of subjects: 57
Study 25095773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol consumption (40% ethanol drinks)
Number of subjects: 8
Study 21853348 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Huoxue Decoction (QRHXD)
Number of subjects: 86
Study 21853348 — intervention group
Group type: COMPARATOR
Intervention: Qingre Huoxue Decoction plus methotrexate (QRHXD+MTX)
Number of subjects: 86
Study 19562716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAAs) 12.45 g/day for at least 1 year
Number of subjects: 56
Study 19562716 — intervention group
Group type: COMPARATOR
Intervention: Control (no BCAAs)
Number of subjects: 56
Study 17223384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (0.5Hz for 5 consecutive days at 100% of rMT)
Number of subjects: 35
Study 17223384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (3000 pulses)
Number of subjects: 35
Study 17223384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Number of subjects: 35
Study 15339742 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized proton magnetic resonance spectroscopy (MRS)
Number of subjects: 2349
Study 12096294 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based nursing intervention (9 visits over 18 weeks)
Number of subjects: 109
Study 12096294 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 109
Study 9500302 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission from cocaine and alcohol dependence during IOP
Number of subjects: 138
Study 9500302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AIDS risk behavior scores in the prior 6 months
Number of subjects: 138
Study 9500302 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention aftercare
Number of subjects: 138
Study 9500302 — intervention group
Group type: COMPARATOR
Intervention: Standard 12‐step focused group aftercare
Number of subjects: 138
Study 7624463 — intervention group
Group type: EXPERIMENTAL
Intervention: High somatic attribution scores (S-FAS)
Number of subjects: 170
Study 7624463 — intervention group
Group type: COMPARATOR
Intervention: Low somatic attribution scores (S-FAS)
Number of subjects: 170
Study 7624463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at follow-up visit
Number of subjects: 170
Study 2676391 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy including positive end-expiratory pressure (PEEP)
Number of subjects: 0
Study 362830 — intervention group
Group type: EXPERIMENTAL
Intervention: cis(Z)-clopenthixol
Number of subjects: 57
Study 362830 — intervention group
Group type: COMPARATOR
Intervention: clopenthixol
Number of subjects: 57
Study 31395587 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation framed towards pulmonary embolus (PE)
Number of subjects: 0
Study 31395587 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation framed away from pulmonary embolus (PE)
Number of subjects: 0
Study 31395587 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation framed towards interstitial lung disease (ILD)
Number of subjects: 0
Study 31395587 — intervention group
Group type: COMPARATOR
Intervention: Control presentation (identical for all)
Number of subjects: 0
Study 27838640 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative itraconazole (4 weeks)
Number of subjects: 100
Study 27838640 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative itraconazole (4 weeks)
Number of subjects: 100
Study 27838640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no itraconazole)
Number of subjects: 100
Study 26048096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 30 mg
Number of subjects: 25
Study 23819229 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating acupuncture at Tianying point
Number of subjects: 90
Study 23819229 — intervention group
Group type: COMPARATOR
Intervention: Warm needling therapy at Tianying point
Number of subjects: 90
Study 21985413 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg minocycline tablet formulation
Number of subjects: 14
Study 19282143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (sulfasalazine, methotrexate, prednisolone)
Number of subjects: 0
Study 19282143 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (sulfasalazine)
Number of subjects: 0
Study 16648512 — intervention group
Group type: EXPERIMENTAL
Intervention: TPZ/CIS (tirapazamine and cisplatin)
Number of subjects: 45
Study 16648512 — intervention group
Group type: COMPARATOR
Intervention: Chemoboost (cisplatin and infusional fluorouracil)
Number of subjects: 45
Study 15001600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.7 g/kg.d)
Number of subjects: 9
Study 15001600 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) (0.3 mg/kg.wk)
Number of subjects: 9
Study 15001600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GLN and rhGH regimen
Number of subjects: 9
Study 15001600 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 9
Study 11893948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cones
Number of subjects: 0
Study 11893948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure biofeedback
Number of subjects: 0
Study 11893948 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises alone
Number of subjects: 0
Study 9304202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone 400 mg i.v.
Number of subjects: 20
Study 9304202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8254832 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate therapy (6 to 8 gm. per day)
Number of subjects: 70
Study 8254832 — intervention group
Group type: COMPARATOR
Intervention: Control (hygienic measures only)
Number of subjects: 70
Study 3533270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 86
Study 3533270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 31521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (2.0 g)
Number of subjects: 70
Study 31521870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 70
Study 29466352 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Over Pain‐Coaching (POP‐C) intervention
Number of subjects: 310
Study 26971267 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured FVA group (preoperative measurement of FVA)
Number of subjects: 120
Study 26971267 — intervention group
Group type: COMPARATOR
Intervention: Control group (fixed FVA at 7°)
Number of subjects: 120
Study 26971267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 24884753 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral support intervention (office practice and peer coach)
Number of subjects: 280
Study 24884753 — intervention group
Group type: COMPARATOR
Intervention: Informational brochures about CHD risk factors (control)
Number of subjects: 280
Study 22517103 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2 mg/day
Number of subjects: 706
Study 22517103 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/day
Number of subjects: 706
Study 22517103 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg/day
Number of subjects: 706
Study 22517103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study 15221324 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic amniocentesis
Number of subjects: 17
Study 15221324 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 17
Study 12042546 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfaxin lavage (8 mL/kg dilute Surfaxin 2.5 mg/mL, instilled into each lung, repeated twice, final lavage with 10 mg/mL)
Number of subjects: 22
Study 12042546 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 22
Study 10534600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine (20 mg increased daily to a maximum of 100 mg)
Number of subjects: 21
Study 10534600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10534600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine
Number of subjects: 21
Study 8519711 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 7.5% dextrose (drug A)
Number of subjects: 44
Study 8519711 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 2.7% dextrose (drug C)
Number of subjects: 44
Study 8519711 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine in 8.25% dextrose (drug B)
Number of subjects: 44
Study 2110937 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 g t.i.d. with meals)
Number of subjects: 9
Study 2110937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 373940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN)
Number of subjects: 18
Study 373940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29098875 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression (intravenous cyclophosphamide up to 1 g/day for two days and methylprednisolone 1 g/day for three days, and then oral dexamethasone 8 mg three-times-a-day for 14 days)
Number of subjects: 299
Study 29098875 — intervention group
Group type: COMPARATOR
Intervention: Saline and placebo tablets (control group)
Number of subjects: 299
Study 29098875 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 299
Study 28823409 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1997
Study 28823409 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1997
Study 25062806 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention delivered by an Occupational Health nurse
Number of subjects: 57
Study 25062806 — intervention group
Group type: COMPARATOR
Intervention: No delivery of brief intervention (control group)
Number of subjects: 57
Study 23609341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential (exercise first)
Number of subjects: 200
Study 23609341 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intervention
Number of subjects: 200
Study 23609341 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-first intervention
Number of subjects: 200
Study 23609341 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 200
Study 23609341 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-first intervention
Number of subjects: 200
Study 21373181 — intervention group
Group type: EXPERIMENTAL
Intervention: Looming sounds
Number of subjects: 2
Study 21373181 — intervention group
Group type: EXPERIMENTAL
Intervention: Receding sounds
Number of subjects: 2
Study 21373181 — intervention group
Group type: COMPARATOR
Intervention: Orthographic plws without sound
Number of subjects: 2
Study 18202556 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 102
Study 18202556 — intervention group
Group type: COMPARATOR
Intervention: Heparinized saline
Number of subjects: 102
Study 16793995 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 164
Study 14676740 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogen only
Number of subjects: 246
Study 14676740 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus 2.5 mg/day medroxyprogesterone acetate
Number of subjects: 246
Study 14676740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 14676740 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent women (those who took > or = 80% of pills)
Number of subjects: 246
Study 10731503 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplements with zinc (15 mg Zn)
Number of subjects: 645
Study 10731503 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid supplements without zinc
Number of subjects: 645
Study 10731503 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplements (both with and without zinc)
Number of subjects: 645
Study 9052292 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 58
Study 9052292 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 58
Study 1392218 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction in personal control over noise
Number of subjects: 105
Study 1392218 — intervention group
Group type: COMPARATOR
Intervention: No instruction in personal control over noise
Number of subjects: 105
Study 1392218 — intervention group
Group type: COMPARATOR
Intervention: Quiet condition
Number of subjects: 105
Study 1392218 — intervention group
Group type: EXPERIMENTAL
Intervention: CCU sound levels
Number of subjects: 105
Study 1392218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to noise
Number of subjects: 105
Study 3890398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms dose), repeated one and six months after initial administration
Number of subjects: 146
Study 3890398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 3890398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms dose)
Number of subjects: 146
Study 31932389 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Dynamiclear
Number of subjects: 292
Study 31932389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 28873333 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided therapy
Number of subjects: 90
Study 28873333 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 90
Study 26988662 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program
Number of subjects: 1635
Study 26988662 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) program
Number of subjects: 1635
Study 24816691 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal implant surgery
Number of subjects: 30
Study 24816691 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency surgery
Number of subjects: 30
Study 22616580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus capecitabine
Number of subjects: 4
Study 22616580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus gemcitabine or capecitabine
Number of subjects: 4
Study 22616580 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib plus paclitaxel
Number of subjects: 4
Study 22616580 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib plus docetaxel and/or letrozole
Number of subjects: 4
Study 20192864 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - 15 patients without periapical lesions
Number of subjects: 30
Study 20192864 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Group (TG) - 15 patients with periapical lesions
Number of subjects: 30
Study 20192864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CG and TG)
Number of subjects: 30
Study 17942510 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 35
Study 17942510 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking training (CWT)
Number of subjects: 35
Study 16207152 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.05 mg/day
Number of subjects: 0
Study 16207152 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.15 mg/day
Number of subjects: 0
Study 16207152 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.5 mg/day
Number of subjects: 0
Study 16207152 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 1.5 mg/day
Number of subjects: 0
Study 16207152 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 5.0 mg/day
Number of subjects: 0
Study 16207152 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 16207152 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin (all doses)
Number of subjects: 0
Study 11910343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (139 +/- 9 mg/d during 39 +/- 2 days)
Number of subjects: 36
Study 11910343 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg)
Number of subjects: 36
Study 11910343 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 microg)
Number of subjects: 36
Study 11910343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10937986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin or Warfarin
Number of subjects: 279
Study 10937986 — intervention group
Group type: COMPARATOR
Intervention: No anti-thrombotic therapy
Number of subjects: 279
Study 8726544 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.6 mg in three divided doses)
Number of subjects: 8
Study 8726544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 1820641 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily artesunate regimen (200 mg initial dose followed by 100 mg daily for 4 days)
Number of subjects: 59
Study 1820641 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily artesunate regimen (100 mg 12 hourly for 2 doses on the first day, followed by 50 mg 12 hourly for another 8 doses)
Number of subjects: 59
Study 7042356 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (800 mg/day)
Number of subjects: 41
Study 7042356 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day)
Number of subjects: 41
Study 30572071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (goal temperature 32–34 °C)
Number of subjects: 281
Study 30572071 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia (goal temperature 36–37.5 °C)
Number of subjects: 281